CDH16

Across TCGA pan-cancer cohorts, CDH16 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CDH16 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CDH16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH16 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

READ, KIRC, and LIHC are the cancer types where CDH16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	39	view →
KIRC	OS	Median	All	0.181	0.805	.002	21	view →
LIHC	OS	Median	All	0.047	0.783	<.001	12	view →
CESC	OS	Median	All	0.277	0.798	.012	6	view →
UCEC	OS	Median	All	0.964	0.653	.038	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	DFS	Median	All	0.761	0.380	.044	2	view →
COAD	DFS	Median	III,IV	1.000	0.384	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CDH16–READ (OS)

Open the READ breakdown →